Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
Gleixner KV, Schneeweiss M, Eisenwort G, Berger D, Herrmann H, Blatt K, Greiner G, Byrgazov K, Hoermann G, Konopleva M, Waliul I, Cumaraswamy AA, Gunning PT, Maeda H, Moriggl R, Deininger M, Lion T, Andreeff M, Valent P. Gleixner KV, et al. Among authors: byrgazov k. Haematologica. 2017 Sep;102(9):1519-1529. doi: 10.3324/haematol.2016.163436. Epub 2017 Jun 8. Haematologica. 2017. PMID: 28596283 Free PMC article.
CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML.
Schneeweiss-Gleixner M, Byrgazov K, Stefanzl G, Berger D, Eisenwort G, Lucini CB, Herndlhofer S, Preuner S, Obrova K, Pusic P, Witzeneder N, Greiner G, Hoermann G, Sperr WR, Lion T, Deininger M, Valent P, Gleixner KV. Schneeweiss-Gleixner M, et al. Among authors: byrgazov k. EBioMedicine. 2019 Dec;50:111-121. doi: 10.1016/j.ebiom.2019.11.004. Epub 2019 Nov 21. EBioMedicine. 2019. PMID: 31761618 Free PMC article.
Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations.
Gleixner KV, Filik Y, Berger D, Schewzik C, Stefanzl G, Sadovnik I, Degenfeld-Schonburg L, Eisenwort G, Schneeweiss-Gleixner M, Byrgazov K, Sperr WR, Mayer J, Lion T, Valent P. Gleixner KV, et al. Among authors: byrgazov k. Am J Cancer Res. 2021 Sep 15;11(9):4470-4484. eCollection 2021. Am J Cancer Res. 2021. PMID: 34659899 Free PMC article.
Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia.
Heller G, Topakian T, Altenberger C, Cerny-Reiterer S, Herndlhofer S, Ziegler B, Datlinger P, Byrgazov K, Bock C, Mannhalter C, Hörmann G, Sperr WR, Lion T, Zielinski CC, Valent P, Zöchbauer-Müller S. Heller G, et al. Among authors: byrgazov k. Leukemia. 2016 Sep;30(9):1861-8. doi: 10.1038/leu.2016.143. Epub 2016 May 23. Leukemia. 2016. PMID: 27211271 Free PMC article.
NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors.
Byrgazov K, Kastner R, Gorna M, Hoermann G, Koenig M, Lucini CB, Ulreich R, Benesch M, Strenger V, Lackner H, Schwinger W, Sovinz P, Haas OA, van den Heuvel-Eibrink M, Niemeyer CM, Hantschel O, Valent P, Superti-Furga G, Urban C, Dworzak MN, Lion T. Byrgazov K, et al. Leukemia. 2017 Jan;31(1):237-240. doi: 10.1038/leu.2016.250. Epub 2015 Aug 30. Leukemia. 2017. PMID: 27573554 Free PMC article. No abstract available.
17 results